论文部分内容阅读
目的:探讨阿那曲唑对绝经后乳腺癌患者性激素水平的影响及对人乳腺癌细胞(MCF-7)的抑制作用.方法:收集80例女性乳腺癌病例,将接受常规管理与他莫昔芬治疗的40例患者纳入对照组;将接受常规管理与阿那曲唑治疗的40例患者纳入观察组.比较两组患者治疗前、治疗3个月后性激素水平变化、疗效及药品不良反应发生率,以及两种药物对MCF-7细胞的抑制作用.结果:治疗后,两组患者雌二醇、孕酮、黄体生成素水平均较治疗前降低,睾酮水平则较治疗前升高(P<0.01);且他莫昔芬组患者雌二醇、孕酮、黄体生成素水平均高于阿那曲唑组,睾酮水平低于阿那曲唑组(P<0.01).两种药物作用72 h的MCF-7细胞抑制率均高于作用48 h(P<0.05);阿那曲唑不同时点的MCF-7细胞抑制率均优于他莫昔芬(P<0.05).对照组患者治疗总有效率(45.0%)低于观察组(70.0%)(P0.05).结论:给予绝经后乳腺癌患者阿那曲唑疗效显著,安全性高,对MCF-7细胞有较强的抑制作用,能有效调节患者性激素水平,减少乳腺癌复发及转移风险.“,”Objective:To investigate the effect of anastrozole on sex hormone levels and michigan cancer foundation-7 ( MCF-7 ) cell inhibition in postmenopausal women with breast cancer. Methods: Totally 80 women with breast cancer were selected. Among them, 40 cases of patients received the routine management and tamoxifen treatment were included into the control group, and another 40 cases of patients received the routine management and anastrozole treatment were included into the observation group. The changes of sex hormone levels, effects and adverse drug reactions of two groups were compared between basetine and three months after treat-ment, meanwhile, the incidence of MCF-7 cell inhibition between two groups. Results:After treatment, the levels of estradiol( ER) , progesterone(PR) and luteotropic hormone(LH) were lower than baselime, however, the level of testosterone was contrary(P <0. 05). Meanwhile, the level of ER, PR and LH in control group were lower than baselime however, the level of testosterone was cont-ray (P<0. 05). The incidence of MCF-7 cell inhibillion between two grugs at time 72 h were higher than the 48 h, the incedence of MCF-7 cell inhibition in observation group were significantly higher than control groups at time 48 h and 72 h (P0. 05). There was no significant differente in the micidence of adverse reactions. Conclusion:Anastrozole used for postmenopausal women with breast cancer has significant effi-cacy, high safety and promising inhibitory effect on MCF-7 cell. It can effectively adjust sex hormone level, reduce occurrence and transfer risks of breast cancer.